diffuse large B-cell lymphoma

Videos

HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL

12/17/2020

Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.

Karl Kilgore, PhD, discusses...

12/17/2020

Journal of Clinical Pathways

Conference Coverage

Comparison of HCRU and Costs Associated With Treatments for Relapsed/Refractory DLBCL

12/06/2020

HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.

HCRU and costs associated with...

12/06/2020

Journal of Clinical Pathways

Guideline Updates

NCCN B-Cell Lymphomas Guideline Features Therapy Updates in Follicular Lymphoma, DLBCL

07/13/2020

The National Comprehensive Cancer Network (NCCN) released an update to its guideline for B-cell lymphomas. In the section for follicular lymphoma with histologic transformation to diffuse large B-cell lymphoma...

The...

07/13/2020

Journal of Clinical Pathways

News

Identifying Biomarkers for Relapsed, Refractory DLBCL Subtype

06/16/2020

A study presented at the European Hematology Association (EHA) Virtual Meeting (June 11-21, 2020) sought to identify biomarkers in patients with relapsed or refractory non-germinal center B-cell-like (non-GCB)...

A...

06/16/2020

Journal of Clinical Pathways

News

Hypercalcemia as a Biomarker for Aggressive Disease in Patients With B-Cell Lymphoma

05/13/2020

For patients with diffuse large B-cell lymphoma (DLBCL), presence of hypercalcemia at diagnosis correlates with negative prognostic factors and a short diagnosis-to-treatment interval, according to a retrospective...

For...

05/13/2020

Journal of Clinical Pathways

Research in Review

Comparative Effectiveness Study Examines Treatment Options for DLBCL

08/18/2017

JCP Editors

A recent study compared the treatment effects and adverse events of first-line chemotherapy regimens in patients with treatment-naïve diffuse large B-cell lymphoma (DLBCL). Rituximab plus cyclophosphamide,...

A...

08/18/2017

Journal of Clinical Pathways

Research in Review

Immunotherapy Better Than Standard of Care for Type of DLBCL

08/03/2017

JCP Editors

Single-agent immunotherapy in patients with a subtype of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) provides more clinical benefit than conventional therapy, according to research published in...

...

08/03/2017

Journal of Clinical Pathways

Research in Review

Prognostic Indicator Identified for Patients With DLBCL

07/14/2017

JCP Editors

Patients with diffuse large B-cell lymphoma (DLBCL) with a specific disease characteristic are expected to have poor clinical outcomes, according to research published in Leukemia (published online July 12, 2017;...

...

07/14/2017

Journal of Clinical Pathways

Research in Review

Does Intensified Therapy Improve Prognosis in DLBCL?

07/03/2017

JCP Editors

Recent research compared the effects of standard chemotherapy dosage with intensified chemotherapy for patients with high-risk diffuse large B-cell lymphoma (DLBCL), published in The Lancet Oncology (published online...

Recent...

07/03/2017

Journal of Clinical Pathways

Research in Review

Intensified Regimens More Effective Than Standard Therapy in DLBCL

06/28/2017

JCP Editors

Intensified regimens improve event-free survival (EFS) and overall survival (OS) in patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL) compared with standard therapy, according to research presented...

...

06/28/2017

Journal of Clinical Pathways